Market Overview

This Small-Cap Vaccine Company Offers 14.5% Upisde, Vetr Crowd Says


Shares of small cap clinical-stage vaccine company Novavax, Inc. (NASDAQ: NVAX) have lost more than 14.5 percent since the beginning of the year. However, since mid-May lows, the stock has managed to recuperate more than 65.5 percent of its value.

Nonetheless, the Vetr crowd seems to believe there is still room for upside left, as evidenced by its average price target of $8.66. This implies a potential return of more than 14.6 percent from current valuations.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided upgrade its rating on shares of Novavax on Wednesday, from 4.0 Stars (Buy) to 4.5 Stars (Strong Buy) - out of a possible 5.0 Stars rating.

It should be noted that, in accordance with the new rating, 71 percent of the crowd’s ratings are bullish.

Latest Ratings for NVAX

Dec 2020JefferiesInitiates Coverage OnBuy
Nov 2020HC Wainwright & Co.MaintainsBuy
Aug 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for NVAX
View the Latest Analyst Ratings


Related Articles (NVAX)

View Comments and Join the Discussion!

Posted-In: VetrUpgrades Price Target Crowdsourcing Analyst Ratings General

Latest Ratings

MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at